These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 9853262)
1. Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kazes I; Delarue F; Hagège J; Bouzhir-Sima L; Rondeau E; Sraer JD; Nguyen G Kidney Int; 1998 Dec; 54(6):1976-84. PubMed ID: 9853262 [TBL] [Abstract][Full Text] [Related]
2. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Li H; Bauzon DE; Xu X; Tschesche H; Cao J; Sang QA Mol Carcinog; 1998 Jun; 22(2):84-94. PubMed ID: 9655252 [TBL] [Abstract][Full Text] [Related]
3. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase. Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143 [TBL] [Abstract][Full Text] [Related]
4. Progesterone differentially regulates the membrane-type matrix metalloproteinase-1 (MT1 -MMP) compartment of proMMP-2 activation in MG-63 cells. Luo XH; Liao EY Horm Metab Res; 2001 Jul; 33(7):383-8. PubMed ID: 11507673 [TBL] [Abstract][Full Text] [Related]
5. Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers. Théret N; Musso O; L'Helgoualc'h A; Campion JP; Clément B Am J Pathol; 1998 Sep; 153(3):945-54. PubMed ID: 9736043 [TBL] [Abstract][Full Text] [Related]
6. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. Cao J; Drews M; Lee HM; Conner C; Bahou WF; Zucker S J Biol Chem; 1998 Dec; 273(52):34745-52. PubMed ID: 9856998 [TBL] [Abstract][Full Text] [Related]
7. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Kazes I; Elalamy I; Sraer JD; Hatmi M; Nguyen G Blood; 2000 Nov; 96(9):3064-9. PubMed ID: 11049985 [TBL] [Abstract][Full Text] [Related]
8. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Jo Y; Yeon J; Kim HJ; Lee ST Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Préaux AM; Mallat A; Nhieu JT; D'Ortho MP; Hembry RM; Mavier P Hepatology; 1999 Oct; 30(4):944-50. PubMed ID: 10498646 [TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829 [TBL] [Abstract][Full Text] [Related]
11. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230 [TBL] [Abstract][Full Text] [Related]
12. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346 [TBL] [Abstract][Full Text] [Related]
13. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Hernandez-Barrantes S; Shimura Y; Soloway PD; Sang QA; Fridman R Biochem Biophys Res Commun; 2001 Feb; 281(1):126-30. PubMed ID: 11178970 [TBL] [Abstract][Full Text] [Related]
14. Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase. Nguyen M; Arkell J; Jackson CJ Lab Invest; 1999 Apr; 79(4):467-75. PubMed ID: 10211999 [TBL] [Abstract][Full Text] [Related]
15. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. Banerji A; Chakraborti J; Mitra A; Chatterjee A J Environ Pathol Toxicol Oncol; 2005; 24(1):3-17. PubMed ID: 15715505 [TBL] [Abstract][Full Text] [Related]
16. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. English WR; Holtz B; Vogt G; Knäuper V; Murphy G J Biol Chem; 2001 Nov; 276(45):42018-26. PubMed ID: 11555661 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. Sato T; Iwai M; Sakai T; Sato H; Seiki M; Mori Y; Ito A Br J Cancer; 1999 Jun; 80(8):1137-43. PubMed ID: 10376963 [TBL] [Abstract][Full Text] [Related]
19. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Caenazzo C; Onisto M; Sartor L; Scalerta R; Giraldo A; Nitti D; Garbisa S Clin Cancer Res; 1998 Sep; 4(9):2179-86. PubMed ID: 9748137 [TBL] [Abstract][Full Text] [Related]
20. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Gilles C; Polette M; Seiki M; Birembaut P; Thompson EW Lab Invest; 1997 May; 76(5):651-60. PubMed ID: 9166284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]